Business Wire

QPS Holdings, LLC Expands Operations in Springfield, Missouri

Share

QPS Holdings, LLC, a global contract research organization has expanded operations in Springfield, Missouri. The new facilities include a clinical (safety) laboratory, an updated self-contained pharmacy, and a new dedicated space to build and ship clinical trial kits. The 2,750-square-foot facility is fully operational as of the fall of 2023 and will give QPS significant flexibility in clinical research study operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231204471818/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

QPS Missouri is a division of QPS Holdings, LLC, a global Contract Research Organization. QPS Missouri conducts Phase I-IV clinical trials in Springfield, Missouri, and has recently added a new safety laboratory, updated pharmacy, and clinical trial kit production facility. (Photo: Business Wire)

The state-of-the art laboratory is equipped with the most up-to-date technologies for Chemistry, Urinalysis, Serology, Coagulation, and Hematology testing, designed to monitor subject safety during ongoing clinical trials. The updated pharmacy now houses multiple fully certified pharmacists and compounding facilities, and the clinical trial kit facility can pick, pack and ship orders anywhere in the world, usually within 24 hours.

“QPS Missouri continues to expand and offer new services in Springfield, and the addition of a safety lab, the updated pharmacy and the clinical trial kit production area were the next steps to enhance our capabilities to provide comprehensive clinical trial services to the local Springfield community,” stated Brendon Bourg, QPS Missouri Vice President, Early Phase Clinical and Head of Administration. “Adding this new safety lab to our local clinical trial facility means that our physicians can receive laboratory results in real-time, adding an additional level of safety for participants. In addition, QPS can now offer these new clinical trial capabilities to our valued clients.”

Over the next few years, Bourg expects these new facilities to grow from providing services for clinical trials running in the Springfield facility, into providing central laboratory, pharmacy, and clinical trial kit-building services for multi-site clinical research projects, expanding the value of the services provided to all QPS clients.

ABOUT QPS HOLDINGS, LLC

QPS Holdings, LLC, is a global clinical research organization (CRO), that supports the preclinical, bioanalytical, and clinical development of new pharmaceutical products. It is headquartered in Newark, Delaware, and has 7 clinical research and development sites that house a mix of preclinical, bioanalytical, and clinical trials research facilities. These sites are in the USA (Delaware, Florida, and Missouri), The Netherlands, Taiwan, China, and India. To learn more about QPS Holdings, LLC, visit https://www.qps.com.

QPS Missouri is a QPS Holdings, LLC flagship clinical site in Springfield, Missouri, USA. The Springfield campus houses 5 independent clinics with over 240 Phase I clinical trial beds, multiple laboratories, a 2,500 square foot negative pressure room, a pharmacy with a clean room, and a new Screening and Recruitment Center. Since opening its doors in Springfield in 1994, QPS Missouri has conducted over 2,100 FDA-regulated studies and paid out over $35 million to as many as 50,000 local participants. To learn more about QPS Missouri, visit https://www.417studies.com .

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Trent Chance
417.831.2048
Trent.Chance@qps.com
https:/417studies.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

KuppingerCole Recognizes Regula as One of the Innovation Leaders in Identity Verification10.6.2025 04:00:00 EEST | Press release

Regula, a global developer of forensic devices and identity verification (IDV) solutions, has made its inaugural appearance in the KuppingerCole Leadership Compass for Identity Verification 2025. Mentioned in the Innovation Leaders category, the company is recognized for its 100% in-house R&D, forensic-grade technology, global document coverage, and advanced liveness detection capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609760424/en/ Regula’s innovative in-house technology powers fast, seamless identity checks—now recognized by KuppingerCole Analysts. Specializing in IDV and cybersecurity industry analysis, KuppingerCole forecasts that the global IDV market will grow from $18.4 billion in 2025 to $50.07 billion by 2030, driven by increasing identity fraud, compliance requirements, user expectations, and technological advancements. As identity verification rapidly shifts toward fully remote and automated e

IFF Appoints Virginia “Gina” Drosos to Board of Directors10.6.2025 00:46:00 EEST | Press release

IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Gina Drosos to its board of directors, effective June 16. Drosos brings more than 30 years of executive leadership experience across the retail, consumer goods, beauty and health care industries. “We are very pleased to welcome Gina to the IFF board,” said Kevin O’Byrne, chair of the board. “Gina brings extensive relevant experience, deep consumer insights and a proven ability to drive innovation and lead with purpose, which aligns with our long-term strategy to deliver sustainable growth and value creation for all stakeholders.” Drosos most recently served as chief executive officer and a director of Signet Jewelers Ltd. (NYSE: SIG)—the world’s largest retailer of diamond jewelry—from August 2017 to November 2024. During her tenure, she led the company through a significant transformation, expanding its digital capabilities and enhancing customer experien

Vantage Data Centers Completes Industry’s First Euro-Based Data Center Asset-Backed Securitization (ABS) with €640M Transaction9.6.2025 19:00:00 EEST | Press release

Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced it has raised €640 million in securitized term notes, marking the first-ever euro-based securitization of data center assets in Continental Europe. The transaction includes an additional €80 million in unfunded Variable Funding Notes. The Class A-2 Notes are rated A-, and the Class B Notes are rated BBB- by Standard & Poor’s and Scope Ratings. This transaction follows Vantage’s success last year with the first-ever EMEA data center ABS completed in British pound sterling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609592365/en/ Pictured is BER11, part of Vantage’s first Berlin campus located in Brandenburg Park. The notes will be used to refinance four data centers in Germany, two in Offenbach, Frankfurt, and two in Berlin, all of which are fully leased to hyperscale customers. The refinancing is part of Vantage’s wider

Uniphore Launches Business AI Cloud: A Sovereign, Composable & Secure AI Platform to Power the Agentic Enterprise9.6.2025 16:04:00 EEST | Press release

Uniphore, the Business AI company, today launched the Uniphore Business AI Cloud: a sovereign, composable, and secure platform that bridges the “AI divide” between IT and business users by combining the simplicity of consumer AI with enterprise-grade security and scalability. While AI technologies rapidly reshape the enterprise, there has been little focus on deploying AI in a way that empowers CIOs to scale it securely across the organization while enabling business users to intuitively access AI with the full power of enterprise data, integrations, and context. IT and business must be united through a single AI platform to fulfill AI’s promise as a transformative force for business. Introducing the Business AI Cloud Uniphore’s Business AI Cloud powers the agentic enterprise with a full-stack AI platform spanning data, knowledge, models, and agents. It empowers business users to deploy AI agents and tap into enterprise knowledge instantly, while giving CIOs the foundation to deliver s

Capcom’s Resident Evil Requiem , the Latest Title in the Series, Set to Release on February 27, 2026!9.6.2025 16:00:00 EEST | Press release

Capcom Co., Ltd. (TOKYO:9697) today announced that Resident Evil Requiem, the latest title in the Resident Evil series, is scheduled for release on February 27, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609946595/en/ Resident Evil Requiem Logo Resident Evil Requiem is a survival horror game that serves as the ninth main installment in the series. The title is being developed using RE ENGINE, Capcom’s proprietary game engine, and leverages Capcom’s extensive development expertise cultivated through numerous hit titles. The graphical fidelity has undergone a significant evolution in particular, delivering visuals with cinematic realism that vividly convey characters’ emotions and offer an unprecedented level of immersion. The company is developing the title steadily to meet the high expectations of both long-time series’ fans and the global gaming audience. Further details regarding the title will be announced in

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye